Tags

Type your tag names separated by a space and hit enter

Bioactivity of prolactin in systemic sclerosis.
Clin Exp Rheumatol. 2004 Mar-Apr; 22(2):145-50.CE

Abstract

OBJECTIVES

To evaluate basal serum prolactin (PRL) levels in systemic sclerosis (SSc) patients with different degrees of skin involvement, and investigate its relationship with some of the clinical and serological parameters of the disease.

METHODS

Basal serum PRL was measured in 44 SSc patients (38 F, 6 M) using a rat NB2 lymphoma line cell proliferation assay. Other parameters measured were: serum aminoterminal propeptide of type III procollagen (PIIINP) by RIA; soluble alpha interleukin-2 receptor (IL-2 sRalpha), serum intercellular adhesion molecule-1 (ICAM-1), von Willebrand factor (vWF) by ELISA; the erythrocyte sedimentation rate (ESR); and C-reactive protein (CRP). Skin and organ/system involvement were assessed according to Medsger et al.'s organ/system severity scale, and global disease activity index according to Valentini et al.

RESULTS

The serum PRL concentration in the SSc patients was 13.8 ng/ml (95%CI from 3.2 to 49.1 ng/ml), similar than that in control subjects (12.8 ng/nl: 95%CI 3.0 to 18.4 ng/ml). Hyperprolactinemia, defined as a level > 20 ng/ml (mean 30.9 ng/ml, median 29.3) was found in a total of 6 cases (13.6%; 95%CI 5.8 to 28%) cases: in 1 out of 6 men (16.7%; 95%CI -26% to 59%) and similarly in 5/38 women (13.2%; 95%CI 1.9% to 24.4%). No correlation was found between PRL levels and SSc subgroup (lcSSc, icSSc, dcSSc), serologial parameters, or the level of disease activity. Finally, no significant correlations were found with clinical or serological variables.

CONCLUSIONS

The findings confirm that mild hyperprolactinemia occurs in at subgroup of SSc patients. However, prospective studies are needed to better define the relationship between PRL and disease activity in scleroderma.

Authors+Show Affiliations

Dipartimento Scientifico di Internistica Clinica e Sperimentale F. Magrassi & A. Lanzara, Seconda Università di Napoli, Naples, Italy. giovanni.lamontagna@unina2.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15083880

Citation

La Montagna, G, et al. "Bioactivity of Prolactin in Systemic Sclerosis." Clinical and Experimental Rheumatology, vol. 22, no. 2, 2004, pp. 145-50.
La Montagna G, Meli R, Criscuolo T, et al. Bioactivity of prolactin in systemic sclerosis. Clin Exp Rheumatol. 2004;22(2):145-50.
La Montagna, G., Meli, R., Criscuolo, T., D'Angelo, S., & Valentini, G. (2004). Bioactivity of prolactin in systemic sclerosis. Clinical and Experimental Rheumatology, 22(2), 145-50.
La Montagna G, et al. Bioactivity of Prolactin in Systemic Sclerosis. Clin Exp Rheumatol. 2004 Mar-Apr;22(2):145-50. PubMed PMID: 15083880.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bioactivity of prolactin in systemic sclerosis. AU - La Montagna,G, AU - Meli,R, AU - Criscuolo,T, AU - D'Angelo,S, AU - Valentini,G, PY - 2004/4/16/pubmed PY - 2004/7/9/medline PY - 2004/4/16/entrez SP - 145 EP - 50 JF - Clinical and experimental rheumatology JO - Clin Exp Rheumatol VL - 22 IS - 2 N2 - OBJECTIVES: To evaluate basal serum prolactin (PRL) levels in systemic sclerosis (SSc) patients with different degrees of skin involvement, and investigate its relationship with some of the clinical and serological parameters of the disease. METHODS: Basal serum PRL was measured in 44 SSc patients (38 F, 6 M) using a rat NB2 lymphoma line cell proliferation assay. Other parameters measured were: serum aminoterminal propeptide of type III procollagen (PIIINP) by RIA; soluble alpha interleukin-2 receptor (IL-2 sRalpha), serum intercellular adhesion molecule-1 (ICAM-1), von Willebrand factor (vWF) by ELISA; the erythrocyte sedimentation rate (ESR); and C-reactive protein (CRP). Skin and organ/system involvement were assessed according to Medsger et al.'s organ/system severity scale, and global disease activity index according to Valentini et al. RESULTS: The serum PRL concentration in the SSc patients was 13.8 ng/ml (95%CI from 3.2 to 49.1 ng/ml), similar than that in control subjects (12.8 ng/nl: 95%CI 3.0 to 18.4 ng/ml). Hyperprolactinemia, defined as a level > 20 ng/ml (mean 30.9 ng/ml, median 29.3) was found in a total of 6 cases (13.6%; 95%CI 5.8 to 28%) cases: in 1 out of 6 men (16.7%; 95%CI -26% to 59%) and similarly in 5/38 women (13.2%; 95%CI 1.9% to 24.4%). No correlation was found between PRL levels and SSc subgroup (lcSSc, icSSc, dcSSc), serologial parameters, or the level of disease activity. Finally, no significant correlations were found with clinical or serological variables. CONCLUSIONS: The findings confirm that mild hyperprolactinemia occurs in at subgroup of SSc patients. However, prospective studies are needed to better define the relationship between PRL and disease activity in scleroderma. SN - 0392-856X UR - https://www.unboundmedicine.com/medline/citation/15083880/Bioactivity_of_prolactin_in_systemic_sclerosis_ L2 - http://www.diseaseinfosearch.org/result/2275 DB - PRIME DP - Unbound Medicine ER -